NASDAQ:ACRS - Aclaris Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.41 -0.13 (-1.99 %) (As of 02/22/2019 01:17 AM ET)Previous Close$6.54Today's Range$6.32 - $6.6552-Week Range$5.95 - $22.41Volume355,102 shsAverage Volume442,634 shsMarket Capitalization$262.40 millionP/E Ratio-2.56Dividend YieldN/ABeta1.3 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania. Receive ACRS News and Ratings via Email Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS Previous Symbol CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone484-324-7933Debt Debt-to-Equity RatioN/A Current Ratio6.53 Quick Ratio6.48Price-To-Earnings Trailing P/E Ratio-2.56 Forward P/E Ratio-1.60 P/E GrowthN/A Sales & Book Value Annual Sales$1.68 million Price / Sales156.19 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book0.88Profitability EPS (Most Recent Fiscal Year)($2.50) Net Income$-68,520,000.00 Net Margins-1,578.24% Return on Equity-63.74% Return on Assets-56.49%Miscellaneous Employees96 Outstanding Shares40,936,000Market Cap$262.40 million Next Earnings Date3/11/2019 (Estimated) OptionableOptionable Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its quarterly earnings data on Friday, August, 3rd. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.04. The biotechnology company earned $3.68 million during the quarter, compared to analysts' expectations of $2.76 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. View Aclaris Therapeutics' Earnings History. When is Aclaris Therapeutics' next earnings date? Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Aclaris Therapeutics. What price target have analysts set for ACRS? 3 brokers have issued 12 month target prices for Aclaris Therapeutics' shares. Their predictions range from $34.00 to $52.00. On average, they expect Aclaris Therapeutics' stock price to reach $45.3333 in the next twelve months. This suggests a possible upside of 607.2% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics. What is the consensus analysts' recommendation for Aclaris Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics. Has Aclaris Therapeutics been receiving favorable news coverage? Press coverage about ACRS stock has been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the near term. Who are some of Aclaris Therapeutics' key competitors? Some companies that are related to Aclaris Therapeutics include Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), CannTrust (CNTTF), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), MacroGenics (MGNX), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Retrophin (RTRX), Radius Health (RDUS), Athenex (ATNX) and ImmunoGen (IMGN). What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Amicus Therapeutics (FOLD), Crispr Therapeutics (CRSP), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Ocular Therapeutix (OCUL), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA) and Sarepta Therapeutics (SRPT). Who are Aclaris Therapeutics' key executives? Aclaris Therapeutics' management team includes the folowing people: Dr. Neal Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)Mr. Frank Ruffo, Co-Founder & CFO (Age 53)Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60) Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.85%), D. E. Shaw & Co. Inc. (5.57%), Broadfin Capital LLC (4.59%), MFN Partners Management LP (3.66%), Foresite Capital Management IV LLC (1.83%) and Aisling Capital Management LP (1.55%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Kamil Ali-Jackson, Neal Walker, Stephen A Tullman and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics. Which institutional investors are selling Aclaris Therapeutics stock? ACRS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Foresite Capital Management III LLC and MetLife Investment Advisors LLC. View Insider Buying and Selling for Aclaris Therapeutics. Which institutional investors are buying Aclaris Therapeutics stock? ACRS stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, MFN Partners Management LP, BlackRock Inc., D. E. Shaw & Co. Inc., Aisling Capital Management LP, Dimensional Fund Advisors LP, Foresite Capital Management IV LLC and Assenagon Asset Management S.A.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics. How do I buy shares of Aclaris Therapeutics? Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $6.41. How big of a company is Aclaris Therapeutics? Aclaris Therapeutics has a market capitalization of $262.40 million and generates $1.68 million in revenue each year. The biotechnology company earns $-68,520,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Aclaris Therapeutics employs 96 workers across the globe. What is Aclaris Therapeutics' official website? The official website for Aclaris Therapeutics is http://www.aclaristx.com. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected] MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 198 (Vote Underperform)Total Votes: 431MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?